[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2919389A - Vaccines - Google Patents

Vaccines

Info

Publication number
AU2919389A
AU2919389A AU29193/89A AU2919389A AU2919389A AU 2919389 A AU2919389 A AU 2919389A AU 29193/89 A AU29193/89 A AU 29193/89A AU 2919389 A AU2919389 A AU 2919389A AU 2919389 A AU2919389 A AU 2919389A
Authority
AU
Australia
Prior art keywords
organisms
basis
vaccines
pathogens
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU29193/89A
Other versions
AU619519B2 (en
Inventor
Steven Neville Chatfield
Gordon Dougan
Carlos Hormaeche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU2919389A publication Critical patent/AU2919389A/en
Application granted granted Critical
Publication of AU619519B2 publication Critical patent/AU619519B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0225Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/10Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An attenuated microorganism harbouring two mutated genes, each of which is located in the organisms aromatic pathway is provided. These organisms can usefully form the basis of a vaccine. They can be genetically engineered so as to express antigens from other pathogens and thus form the basis of a range of multi-valent vaccines.
AU29193/89A 1987-12-23 1988-12-22 Vaccines Expired AU619519B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8730037 1987-12-23
GB878730037A GB8730037D0 (en) 1987-12-23 1987-12-23 Vaccines
PCT/GB1988/001143 WO1989005856A1 (en) 1987-12-23 1988-12-22 Vaccines

Publications (2)

Publication Number Publication Date
AU2919389A true AU2919389A (en) 1989-07-19
AU619519B2 AU619519B2 (en) 1992-01-30

Family

ID=10628973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29193/89A Expired AU619519B2 (en) 1987-12-23 1988-12-22 Vaccines

Country Status (21)

Country Link
EP (1) EP0322237B1 (en)
JP (1) JP2602970B2 (en)
KR (1) KR970010759B1 (en)
AT (1) ATE103331T1 (en)
AU (1) AU619519B2 (en)
BR (1) BR8807376A (en)
CA (1) CA1327331C (en)
DE (1) DE3888652T2 (en)
DK (1) DK174952B1 (en)
ES (1) ES2061700T3 (en)
GB (1) GB8730037D0 (en)
HK (1) HK1000469A1 (en)
HU (2) HU216449B (en)
IE (1) IE65176B1 (en)
IL (1) IL88766A (en)
MY (1) MY104367A (en)
NZ (1) NZ227472A (en)
PH (1) PH31428A (en)
RU (1) RU2114172C1 (en)
WO (1) WO1989005856A1 (en)
ZA (1) ZA889605B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626139B2 (en) * 1989-01-12 1992-07-23 Commonwealth Scientific And Industrial Research Organisation Avirulent salmonella vaccine

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61635B1 (en) * 1990-03-13 1994-11-16 Trinity College Dublin Improvements in vaccines
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
JP3415145B2 (en) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド Expression of recombinant proteins in attenuated bacteria
TW201794B (en) * 1991-05-03 1993-03-11 American Cyanamid Co
CA2156191A1 (en) * 1993-02-22 1994-09-01 Stephen B. Calderwood Heterologous antigens in live cell vaccine strains
WO1998023763A1 (en) * 1996-11-29 1998-06-04 The General Hospital Corporation Heterologous antigens in live cell v. cholerae strains
GB9711964D0 (en) * 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
EP1012232B1 (en) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP0913480A3 (en) * 1997-11-03 2001-07-11 Smithkline Beecham Corporation Chorismate synthase
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
JP4623625B2 (en) 2003-07-24 2011-02-02 株式会社AMBiS Heterotype pentamer recombinant vaccine
FR2898276B1 (en) * 2006-03-08 2008-07-25 Univ Claude Bernard Lyon NOVEL VACCINES FOR THE TREATMENT OR PREVENTION OF PARASITE INFECTIONS OF THE FAMILY OF TAENIDAE AND ESPECIALLY OF THE GENUS ECHINOCOCCUS
RU2593953C2 (en) * 2010-12-22 2016-08-10 Интервет Интернэшнл Бв Vaccine with live bacterial isolates for systemic administration
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337314A (en) * 1979-05-23 1982-06-29 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626139B2 (en) * 1989-01-12 1992-07-23 Commonwealth Scientific And Industrial Research Organisation Avirulent salmonella vaccine

Also Published As

Publication number Publication date
RU2114172C1 (en) 1998-06-27
IE65176B1 (en) 1995-10-04
BR8807376A (en) 1990-03-20
HK1000469A1 (en) 1998-03-27
AU619519B2 (en) 1992-01-30
CA1327331C (en) 1994-03-01
DK412689A (en) 1989-08-22
ZA889605B (en) 1990-08-29
HU890702D0 (en) 1991-01-28
KR970010759B1 (en) 1997-06-30
PH31428A (en) 1998-11-03
HU216449B (en) 1999-06-28
KR890010200A (en) 1989-08-07
NZ227472A (en) 1992-07-28
DK174952B1 (en) 2004-03-22
DK412689D0 (en) 1989-08-22
DE3888652D1 (en) 1994-04-28
JP2602970B2 (en) 1997-04-23
DE3888652T2 (en) 1994-07-07
IE883839L (en) 1989-06-23
ATE103331T1 (en) 1994-04-15
EP0322237A1 (en) 1989-06-28
HUT55242A (en) 1991-05-28
JPH02502785A (en) 1990-09-06
MY104367A (en) 1994-03-31
WO1989005856A1 (en) 1989-06-29
IL88766A (en) 1995-07-31
GB8730037D0 (en) 1988-02-03
ES2061700T3 (en) 1994-12-16
EP0322237B1 (en) 1994-03-23

Similar Documents

Publication Publication Date Title
AU2919389A (en) Vaccines
DE3478469D1 (en) Maltogenic amylase enzyme product, preparation and use thereof
IE853227L (en) Modified polysaccharides and their conjugates with¹immunogenic proteins
EP0020251A3 (en) Dna transfer vector, host transformed with it, vaccine, and their production
AU8331082A (en) Vaccines
AU2152988A (en) Intranasal vaccination of horses with inactivated microorganisms or antigenic material
AU592749B2 (en) Cloning of dna for protozoal antigens
DE3172477D1 (en) Group b streptococcal capsular polysaccharides
EP0297291A3 (en) Outer membrane protein f of pseudomonas aeruginosa
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
ZA796476B (en) Feline infectious peritonitis vaccine
DE3888290D1 (en) Mutants of the infectious bovine rhinotracheitis virus, vaccines containing them, process for their preparation and their use.
ES466359A1 (en) Rabies virus vaccine
AU4627897A (en) Bordetella strain expressing the hybrid FHA, liposomes and vaccines
IL79432A (en) Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms
IL67818A0 (en) Vaccines comprising ozone inactivated organisms and their production
DK145988A (en) Differential pulley with blocks
AU4563793A (en) Bivalent living vaccines against bacterial intestinal pathogenic agents, process for preparing the same, plasmids and strains useful as base material
AU2713488A (en) Process for manufacturing antigens, vaccines and sera to combat bacterial or viral diseases and composition for implementing said process